[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 43 of about 43
1. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer; 2009 Jan 1;115(1):101-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
  • BACKGROUND: Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children.
  • RESULTS: Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients).
  • At the time of ALL diagnosis, the median age was 53 years; cytogenetics were normal in 11 patients, pseudo-diploidy with del(2) in 1 patient, t(9;22) in 1 patient, and unavailable in 3 patients.
  • Frontline therapy included hyper-CVAD in 7 patients, hyper-CVAD with rituximab in 8 patients, and hyper-CVAD with imatinib in 1 patient.
  • Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients.
  • Secondary AML/MDS developed at a median of 32 months after ALL diagnosis.
  • Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS.
  • Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation.
  • The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months).
  • CONCLUSIONS: Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


2. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J, Durrant S, Schwarer A, Bardy P, Herrmann R, Dodds A: Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant; 2007 May;13(5):601-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
  • Recent studies have shown comparable survival outcomes for unrelated donor (URD) stem cell transplantation in chronic myelogenous leukemia compared to sibling donors.
  • We compared outcomes for 105 patients aged 16 to 59 years undergoing URD transplants for acute myelogenous leukemia (AML) who were reported to the Australasian Bone Marrow Transplant Recipient Registry between 1992 and 2002, and a strictly selected matching set of 105 HLA-matched sibling donor (MSD) transplants.
  • There was no significant difference between URD and MSD controls in the distributions of time from diagnosis to transplant, donor-recipient sex match, prior therapies, donor age, or performance status.
  • Both neutrophil and platelet engraftment were significantly more rapid in the sibling group, but transplant-related mortality at 100 days was not significantly different.
  • There was no difference in the cumulative incidence of acute graft-versus-host disease grade II or above at 100 days.
  • Based on this data, URD allografts should be considered in AML patients without a matched sibling donor.
  • This study provides a rationale for a larger prospective study of risk factors in allogeneic transplantation for AML and a guide on the subset of patients who may most benefit from an unrelated donor allograft in AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448920.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Sanz J, Montesinos P, Saavedra S, Lorenzo I, Senent L, Planelles D, Larrea L, Martín G, Palau J, Jarque I, Martínez J, de la Rubia J, Moscardó F, Martinez D, Gómez I, López M, Sanz MA, Sanz GF: Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant; 2010 Nov;16(11):1589-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia.
  • Clinical studies focused on outcomes of umbilical cord blood transplantation (UCBT) for patients with chronic myelogenous leukemia (CML) in need of allogeneic stem cell transplantation and lacking an HLA-matched adult donor are limited.
  • The CI of acute graft-versus-host disease (GVHD) grade II-IV was 61%, that of acute GVHD grade III-IV was 39%, and that of chronic extensive GVHD was 60%.
  • Treatment-related mortality (TRM) was 41% for patients undergoing UCBT while in first or second CP and 100% for patients in AP or BC (P < .01).
  • [MeSH-major] Blood Donors. Cord Blood Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Disease-Free Survival. Female. Graft Rejection / epidemiology. Graft Survival. Graft vs Host Disease / diagnosis. Graft vs Host Disease / epidemiology. Histocompatibility. Humans. Leukocyte Count. Male. Middle Aged. Neutrophils / cytology. Platelet Count. Recurrence. Retrospective Studies. Transplantation Chimera. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20553927.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A, CIBMTR Acute Leukemia Working Committee: HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant; 2008 Feb;14(2):187-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
  • We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute myelogenous leukemia (AML) in first remission.
  • Outcomes of 118 patients receiving HCT and reported to the Center for International Blood and Marrow Transplant Research were compared with 132 similar patients receiving chemotherapy selected from 8 German AML Intergroup multicenter trials.
  • Transplants were associated with higher treatment-related mortality (TRM; relative risk [RR] 6.76, 95% confidence interval [CI] 2.95-15.45, P < .001), lower relapse (RR 0.47, 95% CI 0.25-0.85, P = .01), and similar relapse-free survival (P = .2).
  • Patients without LOS experienced shorter survival after HCT comparing to chemotherapy (RR 3.05, P = .02), whereas patients with LOS had similar survival regardless of postremission therapy.
  • In both cohorts, white blood cell count (WBC) at diagnosis >25 x 10(9)/L was associated with a higher relapse risk (RR = 2.09, P = .03), lower relapse-free (RR = 1.9, P = .008), and OS (RR = 1.91, P = .01).
  • In this cohort of patients with t(8;21) AML, HCT did not improve OS, because reduction of relapse was offset by high TRM.
  • These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3767-75 [10577848.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):300-7 [11167822.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):67-77 [11426630.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]
  • [Cites] Blood. 2002 May 15;99(10):3517-23 [11986202.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):385-400 [12139722.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1525-31 [12176866.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Blood. 2003 Jul 15;102(2):462-9 [12649129.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1521-8 [12886238.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4496-504 [14673036.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):336-44 [15034758.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3741-50 [15289486.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1081-6 [2754449.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1288-95 [8709633.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):165-73 [16939487.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1687-91 [8892667.001]
  • [Cites] Eur J Haematol. 1997 Jul;59(1):47-52 [9260580.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2978-86 [9376578.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • (PMID = 18215779.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-10; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-09; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / U24 CA076518-08; United States / NCI NIH HHS / CA / CA076518-08
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS39951; NLM/ PMC2531160
  •  go-up   go-down


5. Borthakur G, Estey AE: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep; 2007 Sep;9(5):373-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.
  • Therapy-related acute myelogenous leukemia and myelodysplastic syndrome (t-AML/MDS) are increasing in prevalence with aging of the population and improved survival of patients treated with chemotherapy or radiotherapy for other malignancies.
  • Research focused on the pathogenesis of t-AML/MDS will provide insight into the pathogenesis of de novo AML/MDS.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Humans. Neoplasms / drug therapy. Prognosis


6. Betancourt-García RD, Castro J, Fernández AC, López-Enríquez A, Fradera J, Pacheco E: Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature. P R Health Sci J; 2009 Jun;28(2):146-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
  • Therapy-related myelodysplastic syndrome (t-MDS) and therapy-related acute myelogenous leukemia (t-AML) in patients with acute promyelocytic leukemia (APL) are rare events.
  • The cumulative exposure to chemotherapy with alkylating agents and topoisomerase II inhibitors is associated with t-AML that may develop any time after the completion of the treatment.
  • We report the case of an acquired AML who previously received therapy for APL, after two years of being diagnosed.
  • The diagnosis was established by morphologic findings, membrane markers, cytogenetic studies, and fluorescence in situ hybridization (FISH).
  • To our knowledge this is the first documented case in Puerto Rico of a patient with APL that developed a t-AML without the characteristic chromosomal and morphologic findings of APL.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasms, Second Primary / etiology. Translocation, Genetic


7. Pyatt DW, Aylward LL, Hays SM: Is age an independent risk factor for chemically induced acute myelogenous leukemia in children? J Toxicol Environ Health B Crit Rev; 2007 Sep-Oct;10(5):379-400
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is age an independent risk factor for chemically induced acute myelogenous leukemia in children?
  • Secondary or therapy-related acute myelogenous leukemia (t-AML) is a rare but unfortunate consequence of treatment with certain classes of cytotoxic chemotherapeutic agents or chronic exposure to high concentrations of benzene.
  • Drugs known to produce AML following chemotherapy of primary malignancy are usually alkylating agents or topoisomerase II inhibitors.
  • Both children and adults develop AML following treatment with these classes of antineoplastic drugs.
  • In this review, the effect of age at treatment on a child's susceptibility to developing therapy related AML was investigated.
  • As demonstrated in the published literature, the risk of developing AML following chemotherapy is not reliably correlated with the age of the pediatric patient.
  • The age dependency of treatment-related malignancies (all types) in children appears to vary considerably with the type of secondary neoplasm in question.
  • For example, secondary solid tumors such as breast, central nervous system (CNS), bone, and thyroid cancer are highly dependent on the age of the patient at time of diagnosis and treatment; in contrast, an age dependency for t-AML risk was not observed in these same patient populations.
  • Predictably, the induction of t-AML in children follows a rational dose-response relationship, with increasing doses of chemotherapy resulting in greater risk. Recent U.S.
  • Available scientific and medical literature does not support the hypothesis that children necessarily possess an increased risk of developing AML following leukemogenic chemical exposure.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myeloid, Acute / epidemiology. Neoplasms, Second Primary / epidemiology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687725.001).
  • [ISSN] 1521-6950
  • [Journal-full-title] Journal of toxicology and environmental health. Part B, Critical reviews
  • [ISO-abbreviation] J Toxicol Environ Health B Crit Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Topoisomerase II Inhibitors
  • [Number-of-references] 92
  •  go-up   go-down


8. Gutman JA, Leisenring W, Appelbaum FR, Woolfrey AE, Delaney C: Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. Biol Blood Marrow Transplant; 2009 Sep;15(9):1122-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis.
  • Numerous studies confirm the presence of a graft-versus-leukemia (GVL) effect following CBT, and preliminary data suggests that double-unit CBT may be associated with a decreased risk of relapse.
  • We have observed a low relapse rate following CBT among patients with acute leukemias in morphologic complete remission (CR) at the time of myeloablative (MA) transplant.
  • Thirty-one consecutive CBT patients (aged 0.6-42 years, median 22 years), transplanted between April 2006 and June 2008, were compared to matched subjects selected on the basis of disease type and remission number, cytogenetic risk status, minimal residual disease status (MRD), time from diagnosis to first relapse (for patients beyond CR1), use of imatinib for chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) patients, age, and date of transplant.
  • Treatment-related mortality (TRM) between cohorts is comparable.
  • Although we have observed a high incidence of acute graft-versus-host disease (aGVHD) following CBT, the incidence of National Institutes of Health (NIH) consensus criteria chronic GVHD (cGVHD) has been low.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 May 15;97(10):2957-61 [11342417.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1660-5 [2015394.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2265-75 [15564543.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1343-7 [15466923.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Feb;11(2):149-60 [15682076.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1322-30 [17038536.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Apr;13(4):444-53 [17382250.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jun;13(6):655-64 [17531775.001]
  • [Cites] Lancet. 2007 Jun 9;369(9577):1947-54 [17560447.001]
  • [Cites] Blood. 2007 Jul 1;110(1):409-17 [17374741.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Oct;13(10):1145-52 [17889350.001]
  • [Cites] Blood. 2007 Oct 15;110(8):3064-70 [17569820.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4318-27 [18723429.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5183-91 [18768435.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1394-400 [19041062.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2193-200 [18754029.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):256-63 [19064984.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):377-84 [19064980.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1375-82 [18988865.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1631-8 [19104080.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2410-5 [18997171.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1867-71 [2224134.001]
  • (PMID = 19660726.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA009515-24; United States / NCI NIH HHS / CA / T32 CA009515; United States / NCI NIH HHS / CA / T32 CA 009515-24; United States / NCI NIH HHS / CA / T32 CA009515-24
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS119965; NLM/ PMC2723722
  •  go-up   go-down


9. Bhojwani D, Moskowitz N, Raetz EA, Carroll WL: Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia. Paediatr Drugs; 2007;9(3):149-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia.
  • Childhood acute lymphoblastic leukemia (ALL) is a heterogeneous disease.
  • Current treatment approaches are tailored according to the clinical features of the host, genotypic features of the leukemic blast, and early response to therapy.
  • Additional promising utilities include prediction of early response to therapy, overall outcome, and adverse effects.
  • Identification of patients who are predicted to have an unfavorable outcome may allow for early intervention such as intensification of therapy or avoidance of drugs that are associated with specific secondary effects such as therapy-related acute myelogenous leukemia.
  • These newer methods of genome analyses complemented by studies involving the proteome as well as host polymorphisms will have a profound impact on the diagnosis and management of childhood ALL.
  • [MeSH-major] Gene Expression Profiling. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Blood. 2006 Aug 1;108(3):986-92 [16621969.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1186-91 [16154841.001]
  • [Cites] Mol Cell. 2005 Jul 1;19(1):1-13 [15989960.001]
  • [Cites] Leukemia. 2004 Jan;18(1):63-71 [14603332.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):173-83 [12620411.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):365-71 [11726920.001]
  • [Cites] BMC Genomics. 2004 Sep 23;5:71 [15387886.001]
  • [Cites] Blood. 2006 Jul 15;108(2):441-51 [16556894.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):26-35 [15982341.001]
  • [Cites] Leukemia. 2006 Feb;20(2):239-46 [16341039.001]
  • [Cites] Ann Med. 2004;36(7):492-503 [15513300.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Br J Haematol. 2005 Nov;131(4):447-56 [16281934.001]
  • [Cites] Blood. 2002 Jul 15;100(2):420-6 [12091331.001]
  • [Cites] Curr Opin Hematol. 2003 Jul;10(4):290-6 [12799535.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2484-90 [15956279.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Trends Genet. 2006 Feb;22(2):101-9 [16380191.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):117-29 [16491071.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Feb;42(2):107-16 [15543619.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1344-8 [9737681.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Leukemia. 2006 Feb;20(2):264-71 [16357833.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):345-59 [12877662.001]
  • [Cites] Blood. 2006 Jan 15;107(2):769-76 [16189266.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • (PMID = 17523695.001).
  • [ISSN] 1174-5878
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114762
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Oncogene Proteins
  • [Number-of-references] 36
  •  go-up   go-down


10. Faller BA, Robu VG, Borghaei H: Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer. Clin Lung Cancer; 2009 Nov;10(6):438-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer.
  • We present a case of acute myelogenous leukemia with an 11q23/MLL rearrangement diagnosed 1 year after the completion of 4 cycles of cisplatin and vinorelbine for resected NSCLC.
  • To our knowledge, this is the first case of therapy-related acute myelogenous leukemia (t-AML) associated with this chemotherapy combination.
  • The literature on t-AML with the 11q23/MLL rearrangement is reviewed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Translocation, Genetic / drug effects
  • [MeSH-minor] Aged. Carcinoma, Non-Small-Cell Lung / drug therapy. Chromosomes, Human, Pair 11. Cisplatin / administration & dosage. Follow-Up Studies. Histone-Lysine N-Methyltransferase. Humans. Lung Neoplasms / drug therapy. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives


11. Podgornik H, Debeljak M, Zontar D, Cernelc P, Prestor VV, Jazbec J: RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia. Cancer Genet Cytogenet; 2007 Oct 1;178(1):77-81
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia.
  • Amplification of RUNX1 (alias AML1) is a recurrent karyotypic abnormality in childhood acute lymphoblastic leukemia (ALL) that is generally associated with a poor outcome.
  • It does not occur with other primary chromosomal abnormalities in acute ALL.
  • AML1 amplification in acute myelogenous leukemia (AML) is a rare secondary event described mainly in therapy-related cases.
  • AML1 amplification was found in a 13-year-old patient with AML M4/M5 leukemia that occurred 5 years after she had been diagnosed with common B-cell ALL.
  • Conventional cytogenetic, fluorescent in situ hybridization (FISH), and polymerase chain reaction methods revealed no other chromosomal change expected to occur in a disease that we assumed to be a secondary leukemia.
  • This analysis confirmed that in addition to t(12;21), AML1 amplification and overexpression existed already at the time the diagnosis was made.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Regulation, Neoplastic. Leukemia, B-Cell / genetics. Leukemia, B-Cell / pathology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


12. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, Vo K, Molina A: Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol; 2007 Sep 20;25(27):4285-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.
  • PURPOSE: To investigate the incidence of treatment-related myelodysplastic syndrome (t-MDS) and treatment-related acute myelogenous leukemia (t-AML) after treatment with ibritumomab tiuxetan radioimmunotherapy.
  • PATIENTS AND METHODS: Analysis of the incidence of t-MDS and t-AML in 746 patients with non-Hodgkin's lymphoma (NHL) treated with the ibritumomab tiuxetan regimen in registration and compassionate-use trials between 1996 and 2002.
  • RESULTS: Nineteen patients (2.5%) developed t-MDS or t-AML at a median follow-up of 4.4 years (range, 0 to 9.3).
  • These malignancies were diagnosed at a median of 5.6 years (range, 1.4 to 13.9) after the diagnosis of NHL and 1.9 years (range, 0.4 to 6.3) after radioimmunotherapy.
  • The annualized rates were 0.3% per year after the diagnosis of NHL and 0.7% per year after treatment.
  • Most patients with t-MDS or t-AML had multiple cytogenetic aberrations, commonly on chromosomes 5 and 7, suggesting an association with previous exposure to chemotherapy.
  • CONCLUSION: Analysis of data from patients in registration and compassionate-use trials suggests that the annualized incidences of t-MDS and t-AML are consistent with that expected in patients with NHL who have had extensive previous chemotherapy treatment and do not appear to be increased after treatment with the ibritumomab tiuxetan regimen.
  • Cytogenetic testing before treatment with radioimmunotherapy may identify existing chromosomal abnormalities in previously treated patients, particularly those who have been treated with alkylating agents and purine nucleoside analogs and would be at higher risk for t-MDS or t-AML.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Leukemia, Myeloid, Acute / etiology. Lymphoma, Non-Hodgkin / therapy. Myelodysplastic Syndromes / etiology. Radioimmunotherapy / methods. Yttrium Radioisotopes / administration & dosage. Yttrium Radioisotopes / adverse effects


13. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B: Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol; 2006 Aug 1;24(22):3604-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
  • PURPOSE: The risk factors for treatment-related myelodysplastic syndrome (t-MDS) and acute myelogenous leukemia (AML) after autologous stem-cell transplantation (ASCT) are similar to those that increase the risk of difficult stem-cell harvests.
  • We reviewed our experience in 526 patients with lymphoma treated by ASCT to determine whether difficult stem-cell harvests predict for an increased risk of t-MDS/AML.
  • RESULTS: With a median follow-up time for surviving patients of 69 months, 20 patients developed t-MDS/AML, for an actuarial incidence of 6.8% at 10 years.
  • Pretransplantation characteristics, including age, diagnosis of non-Hodgkin's lymphoma or Hodgkin's disease, bone marrow involvement, prior radiation therapy, prior exposure to chemotherapy, lactate dehydrogenase at the time of ASCT, disease status, and method of stem-cell mobilization, were then analyzed with respect to the subsequent development of t-MDS/AML.
  • By multivariable analysis, prior exposure to radiation therapy, four or more chemotherapy regimens, and more than 5 days of apheresis needed to harvest enough stem cells were identified as independent risk factors for t-MDS/AML.
  • CONCLUSION: These results suggest that identifiable pretransplantation factors predict for t-MDS/AML after ASCT.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Lymphoma / surgery. Myelodysplastic Syndromes / etiology. Peripheral Blood Stem Cell Transplantation


14. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud Ø: Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets; 2005 Jun;5(4):229-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies.
  • Acute myelogenous leukemia (AML) is an aggressive disorder with an overall disease-free survival of 40-50% even for the younger patients under 60 years of age who can receive the most intensive treatment.
  • The median age at the time of diagnosis is 60-65 years, and the large majority of elderly patients usually receive less intensive chemotherapy or only supportive therapy due to the high treatment-related mortality when using intensive therapy for elderly individuals.
  • Thus, there is a need for new therapeutic approaches to improve the treatment in younger patients and to make AML-directed therapy with acceptable toxicity possible in elderly individuals.
  • Angiogenesis seems to be important both for leukemogenesis and susceptibility to intensive chemotherapy, and antiangiogenic strategies are therefore considered for the treatment of AML.
  • The two proangiogenic mediators vascular endothelial growth factor (VEGF) and interleukin 8, (IL-8, also referred to as CXCL8) seem to be important in human AML: VEGF is released at increased levels due to interactions between AML cells and neighboring nonleukemic cells, whereas IL-8 is released at high levels by native human AML cells.
  • Thus, VEGF as a therapeutic target in AML is suggested both by experimental and clinical observations, whereas IL-8 as a target is mainly suggested by experimental evidence.
  • In the present review we describe and discuss (i) the angioregulatory network of soluble mediators in AML, including both the systemic levels and local release by native human AML cells; and (ii) various therapeutic approaches to target VEGF and IL-8.
  • Although single angioregulatory mediators can be targeted, it should be emphasized that the final effect of soluble mediators on angioregulation is determined by a complex angioregulatory network that varies between AML patients, and the final effect of targeting single mediators may therefore differ between patient subsets.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Interleukin-8 / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Vascular Endothelial Growth Factor A / drug effects. Vascular Endothelial Growth Factor A / therapeutic use

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975045.001).
  • [ISSN] 1568-0096
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Interleukin-8; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 222
  •  go-up   go-down


15. Natori K, Izumi H, Kaneko K, Ishihara S, Nagase D, Fujimoto Y, Kato M, Umeda M, Kuraishi Y: [Four cases of therapy-related leukemia in multiple myeloma]. Gan To Kagaku Ryoho; 2007 Jan;34(1):121-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Four cases of therapy-related leukemia in multiple myeloma].
  • We have experienced 4 cases of therapy-related leukemia (TRL) in 119 patients with multiple myeloma (MM) who had received combination chemotherapy including alkylating agents between 1988 and 1998.
  • All 4 cases were acute myelogenous leukemia, 3 were males and 1 was female.
  • Median age at diagnosis of MM was 60 years, and median time to TRL from diagnosis of MM was 5.5 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Multiple Myeloma / drug therapy. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220686.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; RYH2T97J77 / ranimustine; VB0R961HZT / Prednisone; CHOP protocol; VMCP protocol
  •  go-up   go-down


16. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, Rijnders BJ: Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis; 2008 Dec 15;47(12):1507-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
  • BACKGROUND: Invasive aspergillosis (IA) is a leading cause of mortality in patients with acute leukemia.
  • METHODS: In 269 patients treated for acute myelogenous leukemia-myelodysplastic syndrome (AML-MDS) during 2002-2007, evidence of IA was collected using high-resolution computed tomography and galactomannan measurement in bronchoalveolar lavage fluid specimens.
  • Diagnostic and therapeutic IA-related costs, corrected for neutropenia duration, were comprehensively analyzed from a hospital perspective.
  • In patients with IA, the mortality rate 12 weeks after starting antifungal therapy was 22% (16 of 73 patients).
  • Total IA-related costs increased to euro 8360 and euro 15,280 for patients with possible and probable or proven IA, respectively, compared with patients without IA (P<.001).
  • CONCLUSIONS: Early diagnosis and treatment of IA with oral voriconazole result in acceptable mortality rates.
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillosis / drug therapy. Aspergillosis / economics. Drug Therapy / economics. Health Care Costs. Leukemia, Myeloid, Acute / complications


17. Ubukata H, Katano M, Takemura A, Kasuga T, Motohashi G, Ge L, Tabuchi T: Acute myelogenous leukemia suddenly developing just after surgery for advanced gastric cancer: report of a case. Surg Today; 2005;35(2):153-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia suddenly developing just after surgery for advanced gastric cancer: report of a case.
  • We report a case of acute myelogenous leukemia (AML) developing just after surgery for advanced gastric cancer, before adjuvant chemotherapy was started.
  • Acute myelogenous leukemia was diagnosed by an aspiration biopsy of the bone marrow.
  • If the AML had developed later and had become remarkable during or after adjuvant chemotherapy, the differential diagnosis between de novo and therapy-related leukemia would have been very difficult.
  • Most leukemias that develop during the course of chemotherapy or radiotherapy, or both, are indisputably considered to be therapy-related.
  • Thus, we report the clinical course of this patient with reference to the related literature to warn surgeons of the possibility of this unusual manifestation.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary / diagnosis. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Bone Marrow Cells / pathology. Humans. Male. Postoperative Complications / diagnosis


18. Tong XZ, Li J, Tan EX, Zhang GC, Wu XY, Peng AH, Zheng D, Zou WY, Hong WD, Luo SK: [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Zhonghua Zhong Liu Za Zhi; 2006 Jul;28(7):545-8
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
  • OBJECTIVE: To retrospectively analyze the curative effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelogenous leukemia patients (CML).
  • Transplant-related mortality occurred in 12 patients.
  • Acute graft-versus-host disease (aGVHD) occurred in 18 patients (51.4%), among them 7 patients (20.0%) were of grade III-IV.
  • CONCLUSION: The patients who had transplantation done within 1 year after diagnosis during their first chronic phase of disease and who had low-grade GVHD have better prognosis.
  • Those patients who had III-IV acute GVHD are prone to incorporate severe infection, which was a worse prognostic factor of allo-HSCT for chronic myelogenous leukemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Transplantation Conditioning

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147125.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T, Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT): Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant; 2006 Jan;37(2):183-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
  • We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to the EBMT.
  • The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leukemia (n = 2) or myeloproliferative syndromes (n = 3).
  • The types of MDS were as follows: RAEB (n = 1; 2%), RAEB-t (n = 3; 5%), or AML (n = 56; 87%).
  • The median time between diagnosis and transplantation was 5 months (range, 3-86).
  • The cumulative incidence of relapse was 58% (95% CI: 44-72%) and of treatment-related mortality 12% (95% CI: 6-38%).
  • Furthermore, age beyond 40 years resulted in a higher treatment-related mortality (47 vs 7%; P = 0.01).
  • Autologous transplantation may cure a substantial number of patients with treatment-related MDS/AML, especially if they are in CR1 and of younger age.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Stem Cell Transplantation


20. Klymenko SV, Bink K, Trott KR, Bebeshko VG, Bazyka DA, Dmytrenko IV, Abramenko IV, Bilous NI, Zitzelsberger H, Misurin AV, Atkinson MJ, Rosemann M: MLL gene alterations in radiation-associated acute myeloid leukemia. Exp Oncol; 2005 Mar;27(1):71-5
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MLL gene alterations in radiation-associated acute myeloid leukemia.
  • AIM: Although acute myelogenous leukemia (AML) arising after radiation exposure is considered to be secondary, little is known about the molecular mechanisms by which the radiation induces the leukemogenic phenotype.
  • The aim of the study was to analyze whether the MLL translocations are as frequent in radiation-associated AML as in spontaneous AML cases.
  • METHODS: Sixty one AML samples obtained at diagnosis were analyzed for the presence of MLL abnormalities using fluorescent in situ hybridization and/or reverse transcription polymerase chain reaction.
  • Of these patients, 27 had experienced radiation exposure due to the Chernobyl accident, 32 were non-irradiated (spontaneous AML), and 2 developed therapy-related AML after chemotherapy with topoisomerase II inhibitors.
  • RESULTS: MLL gene translocations were detected in both groups of spontaneous and therapy-related AML (1/32 and 1/2 cases respectively).
  • The sole MLL rearrangement found in the group of radiation-associated AML patients was a duplication of the gene.
  • CONCLUSION: Our data preclude the involvement of MLL gene translocations in radiation-induced leukemogenesis, but support the assumption that loss and gain of chromosomal material could be crucial in the leukemogenesis of AML patients with the history of radiation exposure due to the Chernobyl accident.
  • [MeSH-major] Chernobyl Nuclear Accident. Chromosome Aberrations / radiation effects. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Leukemia, Myeloid / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812362.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


21. Krug U, Serve H, Müller-Tidow C, Mesters RM, Steffen B, Büchner T, Berdel WE: New molecular therapy targets in acute myeloid leukemia. Recent Results Cancer Res; 2007;176:243-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New molecular therapy targets in acute myeloid leukemia.
  • Despite improvements to acute myelogenous leukemia (AML) therapy during the last 25 years, the majority of patients still succumb to the disease.
  • The present chapter focuses on exciting areas of research in the field of AML therapy, including promising results with regards to recent improvements in our understanding of angiogenesis, tyrosine kinase signaling, farnesylation, cell cycling, modulation of gene expression, protein degradation, modulation of intracellular proteins, apoptosis, metabolism, and the possible retargeting of oncogenic proteins.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Leukemia, Myeloid / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Acute Disease. Apoptosis / drug effects. Cell Cycle / drug effects. Gene Expression / drug effects. Humans. Oncogenes / drug effects. Proteins / drug effects. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607931.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proteins; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 145
  •  go-up   go-down


22. Fontaine MJ, Malone J, Mullins FM, Grumet FC: Diagnosis of transfusion-related acute lung injury: TRALI or not TRALI? Ann Clin Lab Sci; 2006;36(1):53-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of transfusion-related acute lung injury: TRALI or not TRALI?
  • TRALI is a challenging diagnosis for both the transfusion specialist and the clinician.
  • Based on a review of the clinical and laboratory data and applying the Canadian guidelines, the first patient, a 67-yr-old man with chronic myelomonocytic leukemia, was diagnosed as "TRALI" due to the sudden onset of RF requiring intensive resuscitation.
  • [MeSH-major] Blood Transfusion / adverse effects. Respiratory Distress Syndrome, Adult / diagnosis
  • [MeSH-minor] Aged. Anemia, Aplastic / blood. Anemia, Aplastic / therapy. Humans. Infant. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Male. Middle Aged. Respiratory Insufficiency / diagnosis. Respiratory Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501237.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kara IO, Sahin B, Paydas S, Kara B: Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. Leuk Lymphoma; 2005 Jul;46(7):1081-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.
  • A 28-year-old man with relapsed acute myelogenous leukemia (AML-M2) had undergone a non-myeloablative allogeneic peripheral stem cell transplantation.
  • Three years following transplantation, masses were evidenced in his heart by echocardiography but had completely disappeared following a common chemotherapy etoposide, mitoxantrone, ara-C (EMA) regimen for relapsed AML.
  • Here we present the case history and related literature has been reviewed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects. Sarcoma, Myeloid / drug therapy. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Etoposide / administration & dosage. Heart Neoplasms / diagnosis. Heart Neoplasms / drug therapy. Heart Neoplasms / etiology. Humans. Male. Mitoxantrone / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019562.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


24. Ramamoorthy SK, Pandita R, Prakash A, Ramaswamy NV, Al Bahar S: Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice. Acta Haematol; 2007;118(3):141-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
  • Acute leukemia presenting as cholestatic jaundice is rare.
  • It can occur due to granulocytic sarcoma compressing the bile ducts in case of acute myeloid leukemia.
  • We report a case of chronic myeloid leukemia in lymphoid blast cell crisis presenting with severe cholestatic jaundice due to diffuse infiltration of the liver sinusoids with lymphoblasts.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Blast Crisis / drug therapy. Jaundice, Obstructive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Liver Neoplasms / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Diagnosis, Differential. Drug-Related Side Effects and Adverse Reactions. Humans. Imatinib Mesylate. Male


25. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT: Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood; 2008 Oct 15;112(8):3500-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
  • Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML).
  • Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success.
  • Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival.
  • Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival.
  • Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival.
  • Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase.


26. Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y, Stewart S, Stone RM, Tallman MS, McCarthy PL Jr, Hahn T: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant; 2008 Feb;14(2):137-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review.
  • Clinical research examining the role of hematopoietic stem cell transplantation (HSCT) in the therapy of acute myelogenous leukemia (AML) in adults is presented and critically evaluated in this systematic evidence-based review.
  • Treatment recommendations based on the evidence are presented in Table 3, entitled Summary of Treatment Recommendations Made by the Expert Panel for Adult Acute Myelogenous Leukemia, and were reached unanimously by a panel of AML experts.
  • The identified priority areas of needed future research in adult AML include:.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Combined Modality Therapy. Evidence-Based Medicine. Humans. PubMed


27. McCormack E, Bruserud O, Gjertsen BT: Review: genetic models of acute myeloid leukaemia. Oncogene; 2008 Jun 19;27(27):3765-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review: genetic models of acute myeloid leukaemia.
  • The use of genetically engineered mice (GEM) have been critical in understanding disease states such as cancer, and none more so than acute myelogenous leukaemia (AML), a disease characterized by over 100 distinct chromosomal translocations.
  • A substantial proportion of cases exhibiting recurrent reciprocal translocations at diagnosis, such as t(8;21) or t(15;17) have been exhaustively studied and are currently employed in clinical diagnosis.
  • Furthermore, little emphasis has been paid to the effect of chromosomal translocations other than recurrent genetic abnormalities, with no models reflecting the multiple abnormalities observed in high-risk cases of AML accounting for 8-10% of adult AML.
  • Here we review the differing technologies employed in generation of GEM of AML.
  • We discuss the relevance of GEM AML from embryonic stem cell-mediated (for example retinoic acid receptor-alpha fusions and AML1/ETO) models; through to the valuable retroviral-mediated gene transfer models.
  • The latter have been used to great effect in defining the transforming properties of chromosomal translocation products such as MLL (found in 5-6% of all AML cases) and NUP98 (denoting poor prognosis in therapy-related disease) and particularly when co-transduced with bad prognostic factors such as Flt3 mutations.
  • [MeSH-major] Animals, Genetically Modified / genetics. Leukemia, Myeloid, Acute / genetics. Models, Genetic
  • [MeSH-minor] Animals. Chromosome Aberrations. Disease Models, Animal. Exons. Humans. Leukemia, Promyelocytic, Acute / genetics. Mice. Mice, Transgenic. Prognosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264136.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 111
  •  go-up   go-down


28. Faber E, Koza V, Vítek A, Mayer J, Sedlácek P, Zák P, Zapletalová J, Benesová K, Krejcová H, Steinerová K, Maresová I, Cetkovský P: [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005]. Vnitr Lek; 2006 Dec;52(12):1172-80
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
  • In this paper the Czech National Registry of SCT and Transplantation Centre in Pilsen present their joint retrospective analysis of the results of allogeneic SCT in patients with chronic myeloid leukemia (CML) performed in the Czech Republic from 1988 to spring 2005.
  • The median interval from the diagnosis to SCT was 316 days.
  • SCT was complicated by acute graft versus host disease of grade II-IV in 33.7% of patients and by chronic graft versus host disease in 36.3% of patients.
  • Median survival was not reached, 18 (6.1%) of patients died due to the relapse of CML and the cause of 101 (34.2%) deaths was transplant-related.
  • Significant trends were observed during the study period: SCT were performed more frequently in older patients, less than one year from the diagnosis, reduced-intensity conditioning was used more often and the source of hematopoietic stem cells was peripheral blood in the majority of patients (p = 0.188 - < 0.0001).
  • In Cox multivariate analysis the EBMT risk score and the interval from the diagnosis to SCT were identified as independent factors in patient survival.
  • An "ideal" patient, aged under 30, undergoing transplant in the chronic phase of CML within one year since the diagnosis after 2000 had a survival probability of 88% for three years after SCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Chronic Disease. Female. Graft vs Host Disease / diagnosis. Graft vs Host Disease / etiology. Humans. Male. Middle Aged. Recurrence. Transplantation Conditioning. Transplantation, Homologous


29. Barrera M, Atenafu E, Andrews GS, Saunders F: Factors related to changes in cognitive, educational and visual motor integration in children who undergo hematopoietic stem cell transplant. J Pediatr Psychol; 2008 Jun;33(5):536-46
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors related to changes in cognitive, educational and visual motor integration in children who undergo hematopoietic stem cell transplant.
  • RESULTS: Performance IQ improved over time and was negatively related to maternal depression.
  • Full IQ and educational outcomes were positively related to child's age and mother's age.
  • Poor educational outcomes were related to increased time since diagnosis.
  • Maternal age and depression, child's age, and time since diagnosis are critical factors for these outcomes.
  • [MeSH-major] Achievement. Hematopoietic Stem Cell Transplantation / psychology. Intelligence. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy. Neoplasms / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Psychomotor Performance
  • [MeSH-minor] Age Factors. Child. Combined Modality Therapy. Cranial Irradiation / adverse effects. Depression / psychology. Female. Follow-Up Studies. Humans. Male. Mathematics. Mothers / psychology. Prognosis. Reaction Time / radiation effects. Wechsler Scales

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962337.001).
  • [ISSN] 1465-735X
  • [Journal-full-title] Journal of pediatric psychology
  • [ISO-abbreviation] J Pediatr Psychol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Huan C, Wei H, Yu-Hong C, Jing-Zhi W, Yao C, Xiao-Hui Z, Hong-Xia S, Dao-Pei L: HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med; 2008;40(6):444-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
  • BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only proven curative therapy for chronic myeloid leukemia (CML), but lack of human leukocyte antigen (HLA)-matched sibling or unrelated donors has restricted its application.
  • RESULTS: Our data showed that the cumulative incidence of acute graft-versus-host disease (GVHD) was 64.52%, and grade III-IV was 26.45%, 61.79% had chronic GVHD, and 28.93% had extensive chronic GVHD.
  • Probability of 1-year and 4-year leukemia-free survival was similar in chronic phase (CP) 1, CP2/CR2, accelerated phase, and blast crisis patients.
  • Multivariate analysis indicated that factors affecting transplantation outcomes were HLA-B+DR mismatches versus others for II-III acute GVHD and III-IV acute GVHD, the stage of disease at transplantation for relapse, and the time from diagnosis to transplantation for leukemia-free survival, overall survival, and transplantation-related mortality.
  • CONCLUSIONS: For patients lacking an HLA-identical related donor, haploidentical relatives are alternative HSCT donors.
  • [MeSH-major] Blast Crisis / therapy. Hematopoietic Stem Cell Transplantation / methods. Histocompatibility Testing. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy


31. Robin M, Guardiola P, Devergie A, Yeshurun M, Shapiro S, Esperou H, Ribaud P, Rocha V, Gluckman E, Socié G: A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia; 2005 Sep;19(9):1613-20
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors.
  • Long-term survival was adversely affected by: longer time from chronic myeloid leukemia (CML) diagnosis to transplantation, older age at time of transplantation and GvHD (acute grade III-IV or chronic extensive).
  • The main cause of death was infection, related to GvHD in 69% of patients.
  • We conclude that allogeneic transplantation with a related donor can cure more than half of CML patients in chronic phase, although physicians should be alert to long-term complications.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Histocompatibility Testing. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy


32. Cohen PR: Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis; 2007;2:34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.
  • Sweet's syndrome (the eponym for acute febrile neutrophilic dermatosis) is characterized by a constellation of clinical symptoms, physical features, and pathologic findings which include fever, neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis.
  • The malignancy-associated Sweet's syndrome (MASS) can occur as a paraneoplastic syndrome in patients with an established cancer or individuals whose Sweet's syndrome-related hematologic dyscrasia or solid tumor was previously undiscovered; MASS is most commonly related to acute myelogenous leukemia.
  • The dermatosis can precede, follow, or appear concurrent with the diagnosis of the patient's cancer.
  • After initiation of treatment with systemic corticosteroids, there is a prompt response consisting of dramatic improvement of both the dermatosis-related symptoms and skin lesions.
  • The symptoms and lesions of Sweet's syndrome may resolved spontaneously, without any therapeutic intervention; however, recurrence may follow either spontaneous remission or therapy-induced clinical resolution.

  • Genetic Alliance. consumer health - Neutrophilic dermatosis, acute febrile.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1971 Jan;103(1):81-4 [5539508.001]
  • [Cites] Dermatologica. 1971;143(3):153-9 [5131096.001]
  • [Cites] Australas J Dermatol. 1971 Dec;12(3):172-7 [5146931.001]
  • [Cites] Arch Dermatol. 1975 Nov;111(11):1461-3 [1239237.001]
  • [Cites] Am J Med. 1976 Sep;61(3):424-32 [961707.001]
  • [Cites] J Rheumatol. 1977 Summer;4(2):201-6 [881698.001]
  • [Cites] S Afr Med J. 1978 Feb 18;53(7):253-6 [653521.001]
  • [Cites] South Med J. 1978 Nov;71(11):1350-2 [280960.001]
  • [Cites] Rev Prat. 1999 Feb 15;49(4):356-8 [10319682.001]
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 2):838-41 [10321630.001]
  • [Cites] Br J Dermatol. 1999 Jun;140(6):1174-5 [10354095.001]
  • [Cites] Am J Hematol. 1999 Jun;61(2):126-9 [10367792.001]
  • [Cites] Pediatr Cardiol. 1999 Jul-Aug;20(4):295-7 [10368458.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):247-52 [10380046.001]
  • [Cites] Pediatr Infect Dis J. 1999 Jun;18(6):568-70 [10391198.001]
  • [Cites] Br J Dermatol. 1999 Jul;141(1):169-70 [10417544.001]
  • [Cites] Arch Neurol. 1999 Aug;56(8):1010-3 [10448808.001]
  • [Cites] Br J Dermatol. 1964 Aug-Sep;76:349-56 [14201182.001]
  • [Cites] Br J Dermatol. 2004 Nov;151(5):1096-100 [15541094.001]
  • [Cites] Int J Dermatol. 2004 Dec;43(12):938-41 [15569025.001]
  • [Cites] Ann Rheum Dis. 2005 Jan;64(1):168-9 [15608327.001]
  • [Cites] J Am Acad Dermatol. 2005 Feb;52(2):367-9 [15692491.001]
  • [Cites] Orbit. 2005 Mar;24(1):55-7 [15764119.001]
  • [Cites] Arch Dermatol. 2005 Mar;141(3):368-70 [15781678.001]
  • [Cites] Can J Ophthalmol. 2005 Feb;40(1):90-2 [15825540.001]
  • [Cites] J Am Acad Dermatol. 2005 May;52(5):901-5 [15858487.001]
  • [Cites] J Am Acad Dermatol. 2005 May;52(5):927-8 [15858502.001]
  • [Cites] Neurology. 2005 May 24;64(10):1756-61 [15911805.001]
  • [Cites] Hautarzt. 1988 Oct;39(10):658-61 [3069805.001]
  • [Cites] Am J Dermatopathol. 1989 Apr;11(2):99-111 [2653084.001]
  • [Cites] J Am Acad Dermatol. 1989 Apr;20(4):677-80 [2715414.001]
  • [Cites] J Am Acad Dermatol. 1989 Aug;21(2 Pt 2):339-43 [2526826.001]
  • [Cites] Am J Hematol. 1989 Oct;32(2):134-7 [2667344.001]
  • [Cites] Cutis. 1989 Aug;44(2):125-9 [2758862.001]
  • [Cites] Cutis. 1989 Aug;44(2):157-9 [2758865.001]
  • [Cites] Clin Exp Dermatol. 1988 Sep;13(5):344-6 [3256451.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1103-4 [17034566.001]
  • [Cites] Int J Dermatol. 2006 Oct;45(10):1254-5 [17040460.001]
  • [Cites] Int J Dermatol. 2006 Nov;45(11):1365-8 [17076728.001]
  • [Cites] J Am Acad Dermatol. 2006 Dec;55(6):1066-71 [17097401.001]
  • [Cites] Int J Dermatol. 2007 Jan;46(1):106-11 [17214733.001]
  • [Cites] Australas J Dermatol. 2007 Feb;48(1):50-3 [17222305.001]
  • [Cites] J Am Acad Dermatol. 2007 Feb;56(2 Suppl):S61-2 [17224394.001]
  • [Cites] Br J Dermatol. 2007 Mar;156(3):480-5 [17300237.001]
  • [Cites] Intern Med. 2007;46(4):153-4 [17301507.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):275-6 [17310019.001]
  • [Cites] Rev Med Liege. 2006 Dec;61(12):834-6 [17313120.001]
  • [Cites] Presse Med. 2007 Mar;36(3 Pt 1):419-24 [17321363.001]
  • [Cites] J Dermatol. 2007 Apr;34(4):243-7 [17352721.001]
  • [Cites] J Dermatol. 2007 Apr;34(4):258-61 [17352724.001]
  • [Cites] J Am Acad Dermatol. 2007 Apr;56(4):690-3 [17367621.001]
  • [Cites] Ann Dermatol Venereol. 2007 Feb;134(2):151-4 [17375012.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104 [17392386.001]
  • [Cites] Actas Dermosifiliogr. 2007 Mar;98(2):102-4 [17397596.001]
  • [Cites] Am J Dermatopathol. 2007 Apr;29(2):125-33 [17414432.001]
  • [Cites] J Neurol. 2003 Jun;250(6):770-1 [12862039.001]
  • [Cites] Actas Dermosifiliogr. 2005 Jun;96(5):315-6 [16476395.001]
  • [Cites] Clin Exp Dermatol. 2006 Mar;31(2):206-7 [16487091.001]
  • [Cites] J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S122-6 [16488324.001]
  • [Cites] Arch Dermatol. 2006 Feb;142(2):235-40 [16490855.001]
  • [Cites] Korean J Intern Med. 2005 Dec;20(4):346-8 [16491836.001]
  • [Cites] Clin Rheumatol. 2006 Mar;25(2):268-72 [15902518.001]
  • [Cites] J Otolaryngol. 2006 Apr;35(2):144-7 [16527036.001]
  • [Cites] J Infect. 2006 May;52(5):e155-7 [16213026.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Apr;20(4):401-5 [16643136.001]
  • [Cites] Int J Dermatol. 2006 Jun;45(6):677-80 [16796626.001]
  • [Cites] Int J Dermatol. 2006 Jun;45(6):702-8 [16796632.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):1070-1 [16924066.001]
  • [Cites] Arch Dermatol. 2006 Sep;142(9):1170-6 [16983004.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):148 [16856884.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1089-90 [17034556.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1099-101 [17034564.001]
  • [Cites] J Am Acad Dermatol. 1998 Dec;39(6):940-3 [9843005.001]
  • [Cites] Br J Dermatol. 1998 Sep;139(3):555-6 [9767320.001]
  • [Cites] Eur J Dermatol. 1998 Oct-Nov;8(7):503-5 [9854164.001]
  • [Cites] Br J Dermatol. 1998 Oct;139(4):744-5 [9892926.001]
  • [Cites] Br J Dermatol. 1998 Nov;139(5):930-1 [9892977.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Dec;119(6):709-10 [9852556.001]
  • [Cites] Arch Dermatol. 1999 Jan;135(1):62-6 [9923783.001]
  • [Cites] J Rheumatol. 1999 Feb;26(2):440-2 [9972982.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):275-9 [10025763.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 2):331-4 [10025862.001]
  • [Cites] Cutis. 1999 Mar;63(3):177-9 [10190073.001]
  • [Cites] Br J Dermatol. 1999 Mar;140(3):565-6 [10233302.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):341-3 [15223465.001]
  • [Cites] Ann Dermatol Venereol. 2004 Apr;131(4):369-72 [15258512.001]
  • [Cites] J Am Acad Dermatol. 2004 Sep;51(3):474-5 [15337997.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Nov;18(6):716-7 [15482306.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Nov;18(6):745-6 [15482319.001]
  • [Cites] Int J Dermatol. 2004 Oct;43(10):720-2 [15485526.001]
  • [Cites] Int J Dermatol. 2004 Oct;43(10):772-7 [15485540.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):396-9 [15491764.001]
  • [Cites] J Am Acad Dermatol. 1994 Apr;30(4):639-42 [8157792.001]
  • [Cites] Br J Haematol. 1994 Feb;86(2):415-7 [7515269.001]
  • [Cites] Clin Exp Dermatol. 1994 May;19(3):274-7 [8033398.001]
  • [Cites] Br J Haematol. 1994 Mar;86(3):645-8 [7519039.001]
  • [Cites] J Dermatol. 1994 May;21(5):341-6 [8051321.001]
  • [Cites] Int J Dermatol. 1994 Jun;33(6):425-32 [8056477.001]
  • [Cites] Acta Derm Venereol. 1994 May;74(3):229-30 [7915473.001]
  • [Cites] J Am Acad Dermatol. 1994 Oct;31(4):535-56; quiz 557-60 [8089280.001]
  • [Cites] Br J Dermatol. 1979 Jan;100(1):93-9 [427014.001]
  • [Cites] Dermatologica. 1980;160(5):341-7 [7364144.001]
  • [Cites] Br J Dermatol. 1981 Oct;105(4):483 [7295564.001]
  • [Cites] Postgrad Med. 1982 Jan;71(1):55-60 [7054779.001]
  • [Cites] S Afr Med J. 1982 Sep 4;62(11):375-8 [7112306.001]
  • [Cites] Clin Rheum Dis. 1982 Aug;8(2):427-41 [6754235.001]
  • [Cites] Br J Dermatol. 1983 Jan;108(1):99-101 [6821647.001]
  • [Cites] J Pediatr. 1983 Feb;102(2):243-8 [6822929.001]
  • [Cites] Cancer. 1983 Apr 15;51(8):1518-26 [6572088.001]
  • [Cites] Arch Dermatol. 1983 Jul;119(7):610-1 [6574727.001]
  • [Cites] J Am Acad Dermatol. 1983 Jul;9(1):77-81 [6886108.001]
  • [Cites] Cutis. 1983 Aug;32(2):152-4 [6617253.001]
  • [Cites] Arch Intern Med. 1983 Oct;143(10):1993-5 [6625786.001]
  • [Cites] Arch Neurol. 1983 Dec;40(13):829 [6639416.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):751-8 [6358279.001]
  • [Cites] Arch Dermatol. 1984 Feb;120(2):245-7 [6696481.001]
  • [Cites] Blut. 1984 May;48(5):297-305 [6722359.001]
  • [Cites] Arch Dermatol. 1985 Jun;121(6):789-91 [4004304.001]
  • [Cites] Dermatologica. 1985;171(2):102-5 [4043468.001]
  • [Cites] Presse Med. 1985 Sep 14;14(30):1599-601 [2995962.001]
  • [Cites] Lupus. 2005;14(5):399-402 [15934441.001]
  • [Cites] South Med J. 2005 May;98(5):570-2 [15954518.001]
  • [Cites] J Am Acad Dermatol. 2005 Aug;53(2 Suppl 1):S135-8 [16021163.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):834-42 [16027297.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):881-4 [16027305.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):887-9 [16027306.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):893-5 [16027307.001]
  • [Cites] Clin Dev Immunol. 2005 Jun;12(2):145-9 [16050146.001]
  • [Cites] Int J Dermatol. 2005 Aug;44(8):677-80 [16101872.001]
  • [Cites] Retina. 2005 Sep;25(6):800-2 [16141877.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Sep;19(5):597-9 [16164716.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Sep;19(5):634-7 [16164726.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):142 [16197442.001]
  • [Cites] Digestion. 2005;72(2-3):195-200 [16179788.001]
  • [Cites] Acta Gastroenterol Belg. 2005 Jul-Sep;68(3):376-9 [16268426.001]
  • [Cites] Ann Dermatol Venereol. 2005 Nov;132(11 Pt 1):883-5 [16327718.001]
  • [Cites] Int J Dermatol. 2005 Nov;44(11):946-7 [16336530.001]
  • [Cites] Pediatr Dermatol. 2005 Nov-Dec;22(6):525-9 [16354254.001]
  • [Cites] Pediatr Dermatol. 2005 Nov-Dec;22(6):530-5 [16354255.001]
  • [Cites] J Indian Med Assoc. 2005 Aug;103(8):433-5 [16363199.001]
  • [Cites] J Assoc Physicians India. 2005 Aug;53:728-30 [16398086.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):364 [16157374.001]
  • [Cites] Int J Dermatol. 2005 Dec;44(12):1051-3 [16409276.001]
  • [Cites] Arch Dermatol. 2006 Jan;142(1):57-63 [16415387.001]
  • [Cites] Int J Dermatol. 2006 Jan;45(1):51-2 [16426377.001]
  • [Cites] Int J Dermatol. 2006 Jan;45(1):70-80 [16426383.001]
  • [Cites] Ann Dermatol Venereol. 2005 Dec;132(12 Pt 1):1003-6 [16446647.001]
  • [Cites] Haematologica. 2005 Dec;90(12 Suppl):ECR43 [16464758.001]
  • [Cites] South Med J. 2007 Oct;100(10):1057-8 [17943059.001]
  • [Cites] Pediatrics. 1999 Nov;104(5 Pt 1):1142-4 [10545563.001]
  • [Cites] Clin Exp Dermatol. 1999 Sep;24(5):368-71 [10564323.001]
  • [Cites] Australas J Dermatol. 1999 Nov;40(4):204-7 [10570557.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1887-97 [3058878.001]
  • [Cites] J Am Acad Dermatol. 1988 Dec;19(6):983-1005 [3060489.001]
  • [Cites] Am Fam Physician. 1989 Mar;39(3):199-204 [2646883.001]
  • [Cites] Ann Intern Med. 1989 Apr 1;110(7):573-4 [2923392.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):334-59 [9208889.001]
  • [Cites] J Am Acad Dermatol. 1997 Jul;37(1):123-4 [9216537.001]
  • [Cites] Clin Exp Dermatol. 1997 Jan;22(1):54-6 [9330058.001]
  • [Cites] Int J Dermatol. 1997 Sep;36(9):717-8 [9352420.001]
  • [Cites] Br J Dermatol. 1997 Oct;137(4):609-13 [9390341.001]
  • [Cites] Thorac Cardiovasc Surg. 1997 Oct;45(5):247-8 [9402666.001]
  • [Cites] Med Clin (Barc). 1997 Nov 1;109(15):588-91 [9441195.001]
  • [Cites] Int J Dermatol. 1997 Nov;36(11):837-44 [9427076.001]
  • [Cites] Br J Dermatol. 1989 Sep;121(3):413-5 [2803964.001]
  • [Cites] J Pediatr. 1989 Nov;115(5 Pt 1):726-9 [2809903.001]
  • [Cites] J Pediatr. 1989 Nov;115(5 Pt 1):730-4 [2809904.001]
  • [Cites] Vestn Dermatol Venerol. 1989;(11):67-9 [2618175.001]
  • [Cites] Neth J Med. 1990 Feb;36(1-2):62-8 [2278538.001]
  • [Cites] J Rheumatol. 1990 May;17(5):682-4 [2193156.001]
  • [Cites] Rev Clin Esp. 1990 Apr;186(6):264-9 [2203115.001]
  • [Cites] Am J Med. 1990 Sep;89(3):396 [2203266.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):247-9 [2212120.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):503-7 [2212153.001]
  • [Cites] Int J Dermatol. 1990 Dec;29(10):737 [2269574.001]
  • [Cites] Acta Haematol. 1990;84(4):207-8 [2125789.001]
  • [Cites] Dermatologica. 1991;182(1):43-6 [1826487.001]
  • [Cites] Br J Dermatol. 1991 Apr;124(4):348-53 [2025555.001]
  • [Cites] J R Soc Med. 1991 May;84(5):307-8 [2041012.001]
  • [Cites] Acta Derm Venereol. 1991;71(1):77-9 [1676226.001]
  • [Cites] Ann Dermatol Venereol. 1990;117(11):858-60 [2099706.001]
  • [Cites] Australas J Dermatol. 1991;32(1):55-9 [1834046.001]
  • [Cites] Am J Med. 1991 Nov;91(5):553-4 [1951419.001]
  • [Cites] Dermatologica. 1991;183(3):230-3 [1743390.001]
  • [Cites] Acta Derm Venereol. 2003;83(4):290-1 [12926802.001]
  • [Cites] Br J Dermatol. 2003 Sep;149(3):675-7 [14511020.001]
  • [Cites] Int J Dermatol. 2003 Oct;42(10):761-78 [14521689.001]
  • [Cites] Med Clin (Barc). 2003 Oct 4;121(11):437 [14563281.001]
  • [Cites] J Am Acad Dermatol. 2003 Nov;49(5):907-9 [14576675.001]
  • [Cites] Lancet. 2003 Oct 25;362(9393):1374 [14585639.001]
  • [Cites] Korean J Intern Med. 2003 Sep;18(3):187-90 [14619389.001]
  • [Cites] Br J Dermatol. 2003 Oct;149(4):884 [14616386.001]
  • [Cites] Contact Dermatitis. 2003 Jul;49(1):42 [14641120.001]
  • [Cites] J Cutan Pathol. 2004 Jan;31(1):72-6 [14675289.001]
  • [Cites] J Cutan Pathol. 2004 Feb;31(2):189-94 [14690466.001]
  • [Cites] Int J Dermatol. 2004 Jan;43(1):57-9 [14693024.001]
  • [Cites] QJM. 2004 Jan;97(1):55-6 [14702513.001]
  • [Cites] J Am Acad Dermatol. 2004 Feb;50(2):280-5 [14726888.001]
  • [Cites] Clin Nucl Med. 2004 Feb;29(2):91-2 [14734904.001]
  • [Cites] Eye (Lond). 2004 Feb;18(2):214; discussion 214-6 [14762428.001]
  • [Cites] J Laryngol Otol. 2004 Jan;118(1):48-9 [14979973.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Mar;18(2):233 [15009320.001]
  • [Cites] Leuk Res. 2004 May;28 Suppl 1:S61-3 [15036943.001]
  • [Cites] Dermatology. 2004;208(2):175 [15057014.001]
  • [Cites] J Fam Plann Reprod Health Care. 2004 Apr;30(2):115-6 [15086998.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5 Suppl):S90-2 [15097938.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):798-9 [15097971.001]
  • [Cites] Int J Dermatol. 2004 Feb;43(2):95-102 [15125498.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Mar;26(3):197-9 [15125614.001]
  • [Cites] Arch Dermatol. 2004 May;140(5):570-4 [15148101.001]
  • [Cites] J Med Assoc Thai. 2004 May;87(5):567-72 [15222531.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):283-5 [15224368.001]
  • [Cites] Br J Haematol. 1993 Sep;85(1):191-2 [7504506.001]
  • [Cites] Dermatology. 1993;187(4):303-5 [8274797.001]
  • [Cites] Acta Derm Venereol. 1993 Oct;73(5):380-1 [7904408.001]
  • [Cites] J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):293-7 [8294584.001]
  • [Cites] J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):297-300 [8294585.001]
  • [Cites] J Cutan Pathol. 1993 Oct;20(5):465-78 [7507948.001]
  • [Cites] Clin Exp Dermatol. 1994 Jan;19(1):51-2 [8313637.001]
  • [Cites] South Med J. 1994 Feb;87(2):193-6 [8115882.001]
  • [Cites] Int J Dermatol. 2001 Dec;40(12):791-3 [11903682.001]
  • [Cites] Ann Hematol. 2002 Feb;81(2):111-4 [11907794.001]
  • [Cites] Acta Orthop Belg. 2002 Feb;68(1):68-71 [11915462.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Mar;26(3):295-7 [11981477.001]
  • [Cites] Int J Dermatol. 2002 Feb;41(2):107-9 [11982648.001]
  • [Cites] Clin Pediatr (Phila). 2002 Apr;41(3):175-7 [11999681.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):1087-90 [12072085.001]
  • [Cites] J Occup Environ Med. 2002 Jun;44(6):491-2 [12085472.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1596 [8090038.001]
  • [Cites] Am Fam Physician. 1994 Nov 1;50(6):1273-82 [7942426.001]
  • [Cites] J Am Acad Dermatol. 1994 Dec;31(6):1045-7 [7962753.001]
  • [Cites] Pediatr Dermatol. 1994 Sep;11(3):237-40 [7971558.001]
  • [Cites] J Rheumatol. 1994 Sep;21(9):1766-8 [7799365.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):192-8 [7829702.001]
  • [Cites] Mayo Clin Proc. 1995 Mar;70(3):234-40 [7861810.001]
  • [Cites] Leuk Lymphoma. 1994 Oct;15(3-4):261-4 [7532508.001]
  • [Cites] J Am Acad Dermatol. 1995 Mar;32(3):533-5 [7868739.001]
  • [Cites] Int J Dermatol. 1995 Jan;34(1):73-4 [7896497.001]
  • [Cites] Australas J Dermatol. 1994;35(2):91-2 [7702496.001]
  • [Cites] Dermatology. 1995;190(2):160-3 [7727840.001]
  • [Cites] Hum Pathol. 1995 Jun;26(6):687-90 [7774902.001]
  • [Cites] Mayo Clin Proc. 1995 Jun;70(6):605-6 [7632268.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):144-5 [7601939.001]
  • [Cites] Int J Dermatol. 1995 May;34(5):323-9 [7607792.001]
  • [Cites] Am J Med. 1995 Aug;99(2):207-16 [7625426.001]
  • [Cites] Semin Dermatol. 1995 Jun;14(2):173-8 [7640199.001]
  • [Cites] Postgrad Med J. 1995 Jun;71(836):383 [7644412.001]
  • [Cites] Acta Derm Venereol. 1995 May;75(3):237-9 [7653187.001]
  • [Cites] Pediatr Dermatol. 1985 Nov;3(1):40-4 [3906610.001]
  • [Cites] Dermatol Clin. 1985 Jan;3(1):153-63 [3912087.001]
  • [Cites] Cutis. 1986 Mar;37(3):167-74 [3514153.001]
  • [Cites] Am J Med. 1986 Sep;81(3):558-60 [2944382.001]
  • [Cites] Dermatologica. 1986;173(2):85-9 [3792603.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):251, 254 [2434033.001]
  • [Cites] J Clin Pathol. 1987 Feb;40(2):175-9 [3546396.001]
  • [Cites] Am J Med. 1987 Jun;82(6):1220-6 [3300306.001]
  • [Cites] Cutis. 1987 Aug;40(2):139-42 [3621997.001]
  • [Cites] J Assoc Physicians India. 2002 Oct;50:1322-3 [12568224.001]
  • [Cites] Dermatology. 2003;206(2):81-4 [12592072.001]
  • [Cites] J Cutan Pathol. 2003 Apr;30(4):261-4 [12680958.001]
  • [Cites] Int J Dermatol. 2003 Jun;42(6):438-43 [12786869.001]
  • [Cites] Clin Exp Dermatol. 2003 Jul;28(4):377-9 [12823297.001]
  • [Cites] J Am Acad Dermatol. 2003 Jul;49(1):132-8 [12833027.001]
  • [Cites] Ann Acad Med Singapore. 2003 May;32(3):411-4 [12854387.001]
  • [Cites] Clin Exp Dermatol. 1987 Sep;12(5):345-9 [3446421.001]
  • [Cites] Tunis Med. 2007 Jan;85(1):49-53 [17424710.001]
  • [Cites] South Med J. 2007 Apr;100(4):414-5 [17458409.001]
  • [Cites] Ann Pharmacother. 2007 May;41(5):802-11 [17426076.001]
  • [Cites] Int J Dermatol. 2007 May;46(5):496-9 [17472681.001]
  • [Cites] Clin Rheumatol. 2007 Jul;26(7):1215-6 [17294051.001]
  • [Cites] Australas J Dermatol. 2007 May;48(2):105-9 [17535199.001]
  • [Cites] Int J Dermatol. 2007 Jun;46(6):571-4 [17550553.001]
  • [Cites] Clin Dermatol. 2007 May-Jun;25(3):326-33 [17560310.001]
  • [Cites] J Cutan Pathol. 2007 Jul;34(7):526-34 [17576331.001]
  • [Cites] Ann Hematol. 2007 Aug;86(8):613-4 [17468870.001]
  • [Cites] Med Sci Monit. 2007 Apr;13(4):CS53-5 [17392656.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):989-90 [8959963.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):995-7 [8959967.001]
  • [Cites] Arch Dermatol. 1996 Dec;132(12):1507, 1510 [8961884.001]
  • [Cites] Br J Dermatol. 1997 Jan;136(1):142-4 [9039324.001]
  • [Cites] Br J Dermatol. 1997 Feb;136(2):296-7 [9068763.001]
  • [Cites] J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):436-9 [9091476.001]
  • [Cites] Dermatology. 1997;194(2):182-4 [9094473.001]
  • [Cites] Int J Dermatol. 1997 Apr;36(4):292-3 [9169331.001]
  • [Cites] Med Pediatr Oncol. 2003 Feb;40(2):135-6 [12461805.001]
  • [Cites] Ann Rheum Dis. 2003 Jan;62(1):81-2 [12480678.001]
  • [Cites] Int J Dermatol. 2002 Dec;41(12):928-30 [12492993.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):101-2 [12533182.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):102 [12533183.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1033-4 [10570395.001]
  • [Cites] Br J Ophthalmol. 1998 Mar;82(3):328-9 [9602638.001]
  • [Cites] Br J Dermatol. 1998 Feb;138(2):365-6 [9602899.001]
  • [Cites] Clin Exp Dermatol. 1997 Nov;22(6):269-73 [9604452.001]
  • [Cites] Australas J Dermatol. 1998 May;39(2):116-8 [9611384.001]
  • [Cites] Dermatology. 1998;196(3):346-7 [9621146.001]
  • [Cites] Eur Respir J. 1998 Apr;11(4):978-80 [9623707.001]
  • [Cites] Am J Hematol. 1998 Aug;58(4):337-8 [9692401.001]
  • [Cites] Med Pediatr Oncol. 1998 Sep;31(3):178-81 [9722904.001]
  • [Cites] Br J Dermatol. 1998 Jul;139(1):107-10 [9764159.001]
  • [Cites] Ann Hematol. 1998 Sep;77(3):135-8 [9797084.001]
  • [Cites] Dermatology. 1998;197(2):195-6 [9840982.001]
  • [Cites] Intensive Care Med. 1998 Oct;24(10):1106-9 [9840248.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):766-7 [10583147.001]
  • [Cites] Br J Dermatol. 1999 Nov;141(5):943-4 [10583195.001]
  • [Cites] J Clin Gastroenterol. 1999 Dec;29(4):349-50 [10599643.001]
  • [Cites] Clin Exp Dermatol. 1999 Nov;24(6):443-5 [10606943.001]
  • [Cites] Leuk Res. 2000 Jan;24(1):83-6 [10634651.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 2):332-4 [10640926.001]
  • [Cites] Am J Med. 2000 Apr 1;108(5):434-5 [10759106.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Apr;89(4):477-9 [10760730.001]
  • [Cites] J Am Acad Dermatol. 2000 May;42(5 Pt 2):932-5 [10767709.001]
  • [Cites] Arch Dermatol. 2000 May;136(5):673-4 [10815868.001]
  • [Cites] Australas J Dermatol. 1991;32(2):61-4 [1781756.001]
  • [Cites] J Am Acad Dermatol. 1991 Oct;25(4):734 [1724249.001]
  • [Cites] Arthritis Rheum. 1992 Apr;35(4):484-6 [1567500.001]
  • [Cites] Dermatologica. 1991;183(4):255-64 [1809587.001]
  • [Cites] Ann Intern Med. 1992 Jun 15;116(12 Pt 1):996-8 [1375012.001]
  • [Cites] J Rheumatol. 1992 May;19(5):814-20 [1613717.001]
  • [Cites] Am Rev Respir Dis. 1992 Jul;146(1):269 [1626811.001]
  • [Cites] Cutis. 1992 Jun;49(6):448-50 [1628515.001]
  • [Cites] Intern Med. 1992 May;31(5):686-9 [1504437.001]
  • [Cites] Aust N Z J Ophthalmol. 1992 Aug;20(3):263-5 [1449782.001]
  • [Cites] Int J Dermatol. 1992 Sep;31(9):670-1 [1459771.001]
  • [Cites] Acta Haematol. 1992;88(2-3):154-7 [1466198.001]
  • [Cites] Br J Dermatol. 1992 Nov;127(5):538-9 [1467297.001]
  • [Cites] J Am Acad Dermatol. 1992 Nov;27(5 Pt 2):801-4 [1469130.001]
  • [Cites] Pediatr Dermatol. 1992 Sep;9(3):288-92 [1488383.001]
  • [Cites] Clin Exp Dermatol. 1993 Jan;18(1):47-9 [8440052.001]
  • [Cites] Cutis. 1993 Mar;51(3):175-9 [8444048.001]
  • [Cites] Cutis. 1993 Feb;51(2):112-4 [8453891.001]
  • [Cites] Int J Dermatol. 1993 Apr;32(4):261-8 [8486457.001]
  • [Cites] Arch Ophthalmol. 1993 May;111(5):587-8 [8489431.001]
  • [Cites] Mayo Clin Proc. 1993 Jun;68(6):620-1 [8497142.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):584-6 [8504055.001]
  • [Cites] Clin Dermatol. 1993 Jan-Mar;11(1):149-57 [8339190.001]
  • [Cites] Arch Dermatol. 1993 Aug;129(8):1062-4 [8352617.001]
  • [Cites] Obstet Gynecol Surv. 1993 Aug;48(8):584-7 [8371901.001]
  • [Cites] Br J Haematol. 1993 Jun;84(2):356-8 [7691149.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2723-31 [8402496.001]
  • [Cites] Australas J Dermatol. 1993;34(1):31-3 [8240185.001]
  • [Cites] Korean J Intern Med. 2001 Sep;16(3):218-21 [11769583.001]
  • [Cites] Dermatology. 2002;204(1):84 [11834860.001]
  • [Cites] J Dermatol. 2002 Feb;29(2):91-5 [11890302.001]
  • [Cites] Am J Clin Dermatol. 2002;3(2):117-31 [11893223.001]
  • [Cites] Int J Dermatol. 2002 Jan;41(1):28-31 [11895510.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):345-9 [11902985.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):361-5 [11902987.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):400-3 [11902994.001]
  • [Cites] Clin Dermatol. 2000 May-Jun;18(3):265-82 [10856659.001]
  • [Cites] Arch Intern Med. 2000 Jun 26;160(12):1869 [10871983.001]
  • [Cites] Acta Derm Venereol. 2000 Mar-Apr;80(2):145-6 [10877140.001]
  • [Cites] Eur J Haematol. 2000 Jul;65(1):72-3 [10914942.001]
  • [Cites] Br J Dermatol. 2000 Aug;143(2):449-50 [10951165.001]
  • [Cites] J Am Acad Dermatol. 2000 Oct;43(4):691-7 [11004629.001]
  • [Cites] Am J Dermatopathol. 2000 Oct;22(5):429-33 [11048979.001]
  • [Cites] Postgrad Med J. 2000 Nov;76(901):713-4 [11060149.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):914-6 [11069494.001]
  • [Cites] Int J Dermatol. 2000 Oct;39(10):795-8 [11095204.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1322-4 [11122045.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jan;23(1):59-62 [11196274.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):870-4 [11050599.001]
  • [Cites] J Cutan Pathol. 2001 Feb;28(2):90-6 [11168757.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):862-4 [11312438.001]
  • [Cites] Medicine (Baltimore). 2001 May;80(3):173-9 [11388093.001]
  • [Cites] Acta Derm Venereol. 2001 Jan-Feb;81(1):73-4 [11411932.001]
  • [Cites] Am J Med. 2001 Jul;111(1):80-1 [11460854.001]
  • [Cites] J Am Acad Dermatol. 2001 Aug;45(2):300-2 [11464196.001]
  • [Cites] J Neurol Sci. 2001 Jul 15;188(1-2):95-7 [11489291.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1106-8 [11493115.001]
  • [Cites] Yale J Biol Med. 2001 May-Jun;74(3):165-8 [11501712.001]
  • [Cites] J Am Acad Dermatol. 2001 Sep;45(3):325-61; quiz 362-4 [11511831.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):590-5 [11568752.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1526-9 [11598485.001]
  • [Cites] Clin Exp Dermatol. 2001 Nov;26(8):668-70 [11722452.001]
  • [Cites] Dermatology. 1995;190(4):335-7 [7655121.001]
  • [Cites] J Am Acad Dermatol. 1995 Sep;33(3):393-410; quiz 410-2 [7544812.001]
  • [Cites] Clin Exp Dermatol. 1995 May;20(3):279-80 [7671433.001]
  • [Cites] Arch Dermatol. 1995 Oct;131(10):1175-7 [7574835.001]
  • [Cites] Aust Fam Physician. 1995 Oct;24(10):1867-9 [8546614.001]
  • [Cites] Am J Med. 1995 Dec;99(6):662-71 [7503090.001]
  • [Cites] Br J Dermatol. 1995 Sep;133(3):483-6 [8547011.001]
  • [Cites] Br J Dermatol. 1995 Sep;133(3):490-1 [8547013.001]
  • [Cites] Lancet. 1996 Mar 9;347(9002):690 [8596402.001]
  • [Cites] J Am Acad Dermatol. 1996 Mar;34(3):539 [8609279.001]
  • [Cites] Pediatrics. 1996 Mar;97(3):401-3 [8604280.001]
  • [Cites] Leukemia. 1996 Apr;10(4):731-4 [8618455.001]
  • [Cites] J Am Acad Dermatol. 1996 May;34(5 Pt 2):918-23 [8621829.001]
  • [Cites] Cutis. 1996 Feb;57(2):107-10 [8646854.001]
  • [Cites] Adv Dermatol. 1996;11:215-52; discussion 253 [8718480.001]
  • [Cites] Australas J Dermatol. 1996 May;37(2):99-101 [8687337.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Mar;32B(2):133-6 [8736177.001]
  • [Cites] Br J Dermatol. 1996 Apr;134(4):705-9 [8733376.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 Aug;18(3):282-4 [8689342.001]
  • [Cites] Clin Exp Dermatol. 1996 Mar;21(2):175 [8759219.001]
  • [Cites] Am J Med. 1996 Aug;101(2):231-3 [8757366.001]
  • [Cites] Ann Acad Med Singapore. 1996 Mar;25(2):222-7 [8799010.001]
  • [Cites] J Neurol. 1996 Jul;243(7):556-7 [8836949.001]
  • [Cites] Int J Dermatol. 1996 Jan;35(1):9-15 [8838921.001]
  • [Cites] Respir Med. 1996 Jan;90(1):57-9 [8857328.001]
  • [Cites] J Am Acad Dermatol. 1996 Oct;35(4):629-31 [8859296.001]
  • [Cites] Haematologica. 1996 Jan-Feb;81(1):54-8 [8900854.001]
  • [Cites] J Rheumatol. 1996 Nov;23(11):1995-8 [8923382.001]
  • [Cites] J Cutan Pathol. 2002 May;29(5):301-4 [12100632.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):323-4 [12140489.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):397-8 [12185512.001]
  • [Cites] Br J Dermatol. 2002 Sep;147(3):558-62 [12207601.001]
  • [Cites] Rheumatology (Oxford). 2002 Sep;41(9):1067-9 [12209043.001]
  • [Cites] Acta Derm Venereol. 2002;82(3):221 [12353722.001]
  • [Cites] Am J Psychiatry. 2002 Nov;159(11):1947 [12411238.001]
  • [Cites] Eur J Radiol. 2002 Nov;44(2):139-42 [12413682.001]
  • (PMID = 17655751.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 435
  • [Other-IDs] NLM/ PMC1963326
  •  go-up   go-down


33. Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ: Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant; 2008 Mar;14(3):282-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.
  • Unrelated umbilical cord blood (UCB) has been investigated as an alternative stem cell source to suitably HLA matched related (MRD) and adult volunteer unrelated donors.
  • We hypothesized that RIC HCT using UCB would be safe and efficacious in older patients, and compared the treatment-related mortality (TRM) and overall survival (OS) of RIC HCT in patients older than 55 years using either MRD (n = 47) or, in patients with no 5 of 6 or 6 of 6 HLA compatible related donors, UCB (n = 43).
  • The median age of MRD and UCB cohorts was 58 (range, 55-70) and 59 (range, 55-69) years, respectively. acute myelogenous leukemia/myelodysplastic syndrome (AML/MDS) (50%) was the most common diagnosis.
  • The cumulative incidence of grade II-IV acute graft-versus-host (aGVHD) disease (42% versus 49%, P = .20) and TRM at 180-days (23% versus 28%, P = .36) were comparable.
  • The use of RIC and UCB extends the availability of transplant therapy to older patients previously excluded on the basis of age and lack of a suitable MRD.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1993-2003 [15774790.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1343-7 [15466923.001]
  • [Cites] Leukemia. 2005 Jan;19(1):7-12 [15526016.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] Stat Med. 1997 Apr 30;16(8):901-10 [9160487.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10119-22 [7479737.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1636-42 [7632974.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1954-63 [7703498.001]
  • [Cites] Semin Hematol. 1991 Jul;28(3):250-9 [1887253.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2021-30 [12791654.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1915-9 [12738676.001]
  • [Cites] Transplantation. 2003 Jun 27;75(12):2135-43 [12829926.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Aug;11(4):731-7 [12201962.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1611-8 [12176879.001]
  • [Cites] Bone Marrow Transplant. 2002 Feb;29(3):243-8 [11859397.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3390-400 [11369628.001]
  • [Cites] Blood. 2001 May 15;97(10):2962-71 [11342418.001]
  • [Cites] Blood. 2001 May 15;97(10):2957-61 [11342417.001]
  • [Cites] Clin Transpl. 1999;:121-7 [11038630.001]
  • [Cites] Hum Immunol. 2000 Aug;61(8):834-40 [10980395.001]
  • [Cites] N Engl J Med. 2000 Jun 22;342(25):1846-54 [10861319.001]
  • [Cites] Blood. 2007 Oct 15;110(8):3064-70 [17569820.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Oct;13(10):1145-52 [17889350.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jul;13(7):844-52 [17580263.001]
  • [Cites] Curr Opin Immunol. 2006 Oct;18(5):571-5 [16895752.001]
  • [Cites] Bone Marrow Transplant. 2006 Jul;38(2):83-93 [16751788.001]
  • [Cites] Haematologica. 2006 Jun;91(6):852-5 [16769592.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 May;12(5):560-5 [16635791.001]
  • [Cites] Blood. 2006 May 1;107(9):3804-7 [16384924.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(4):339-44 [16415898.001]
  • (PMID = 18275894.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA065493-110009; United States / NCI NIH HHS / CA / P01 CA065493; United States / NCI NIH HHS / CA / P01 CA065493-120009; United States / NCI NIH HHS / CA / P01CA65493; United States / NCI NIH HHS / CA / CA065493-120009; United States / NCI NIH HHS / CA / CA065493-110009
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists
  • [Other-IDs] NLM/ NIHMS41246; NLM/ PMC2674378
  •  go-up   go-down


34. Yamamoto M, Kakihana K, Kurosu T, Murakami N, Miura O: Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet; 2005 Mar;157(2):104-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
  • The BCR/ABL tyrosine kinase inhibitor imatinib has shown remarkable efficacy in treating patients with chronic myelogenous leukemia (CML).
  • Leukemic cells from the patient were found to express the fusion transcript of NUP98 and DDX10, which is in accordance with previously reported cases of de novo or therapy-related acute myelogenous leukemia and myelodysplastic syndrome with inv(11)(p15q22).
  • These observations raise a possibility that the NUP98/DDX10 fusion might be involved in imatinib resistance as well as in acute transformation of CML.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 11. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Nuclear Pore Complex Proteins / genetics. Oncogene Proteins, Fusion / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721630.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Nuclear Pore Complex Proteins; 0 / Nup98 protein, human; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / nuclear pore complex protein 98; 8A1O1M485B / Imatinib Mesylate; EC 3.6.1.- / DDX10 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases; EC 3.6.4.13 / RNA Helicases
  •  go-up   go-down


35. Carneiro BA, Kaminer L, Eldibany M, Sreekantaiah C, Kaul K, Locker GY: Oxaliplatin-related acute myelogenous leukemia. Oncologist; 2006 Mar;11(3):261-2
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin-related acute myelogenous leukemia.
  • Bone marrow biopsy was consistent with therapy-related acute myelogenous leukemia.
  • It is likely that the leukemia was related to the oxaliplatin administration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Cecal Neoplasms / drug therapy. Cecal Neoplasms / pathology. Chromosome Deletion. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Middle Aged. Omentum / pathology. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / secondary. Trisomy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549810.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


36. Swiers G, de Bruijn M, Speck NA: Hematopoietic stem cell emergence in the conceptus and the role of Runx1. Int J Dev Biol; 2010;54(6-7):1151-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Runx1 is famous for its role in HSC emergence, and notorious for its involvement in leukemia, as chromosomal rearrangements and inactivating mutations in the human RUNX1 gene are some of the most common events in de novo and therapy-related acute myelogenous leukemia, myelodysplastic syndrome and acute lymphocytic leukemia.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20711992.001).
  • [ISSN] 1696-3547
  • [Journal-full-title] The International journal of developmental biology
  • [ISO-abbreviation] Int. J. Dev. Biol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL100405; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit
  • [Other-IDs] NLM/ NIHMS578062; NLM/ PMC4512753
  •  go-up   go-down


37. Funk RK, Maxwell TJ, Izumi M, Edwin D, Kreisel F, Ley TJ, Cheverud JM, Graubert TA: Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice. Blood; 2008 Aug 15;112(4):1434-42
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice.
  • Therapy-related acute myelogenous leukemia (t-AML) is an important late adverse effect of alkylator chemotherapy.
  • Susceptibility to t-AML has a genetic component, yet specific genetic variants that influence susceptibility are poorly understood.
  • We analyzed an F(2) intercross (n = 282 mice) between mouse strains resistant or susceptible to t-AML induced by the alkylator ethyl-N-nitrosourea (ENU) to identify genes that regulate t-AML susceptibility.
  • Each mouse carried the hCG-PML/RARA transgene, a well-characterized initiator of myeloid leukemia.
  • In the absence of ENU treatment, transgenic F(2) mice developed leukemia with higher incidence (79.4% vs 12.5%) and at earlier time points (108 days vs 234 days) than mice in the resistant background.
  • Thirteen QTLs significantly associated with leukemia-free survival, spleen weight, or white blood cell count were identified on 8 chromosomes.
  • These results suggest that susceptibility to ENU-induced leukemia in mice is a complex trait governed by genes at multiple loci.
  • Improved understanding of genetic risk factors should lead to tailored treatment regimens that reduce risk for patients predisposed to t-AML.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15103-8 [10611345.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1919-28 [16167058.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):109-17 [11225603.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):255-76 [11378539.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5029-38 [16707424.001]
  • [Cites] Heredity (Edinb). 1992 Oct;69(4):315-24 [16718932.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(2):59-70 [17143301.001]
  • [Cites] Br J Haematol. 2007 Feb;136(4):590-6 [17367411.001]
  • [Cites] Br J Haematol. 2007 Jun;137(6):513-29 [17539774.001]
  • [Cites] Br J Radiol. 2007 Sep;80 Spec No 1:S56-62 [17704327.001]
  • [Cites] Oncogene. 2001 Dec 13;20(57):8281-6 [11781843.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1972-6 [12200354.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Exp Toxicol Pathol. 2002 Nov;54(3):193-6 [12484555.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2015-23 [12393427.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2123-37 [12775738.001]
  • [Cites] Leukemia. 2004 Jan;18(1):120-5 [14586477.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):325-45 [3950675.001]
  • [Cites] Genetics. 1989 Jan;121(1):185-99 [2563713.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3091-6 [7684624.001]
  • [Cites] Mutat Res. 1994 Apr 1;306(1):19-34 [7512200.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):1063-73 [8164031.001]
  • [Cites] Leuk Lymphoma. 1996 Feb;20(5-6):365-72 [8833391.001]
  • [Cites] Blood. 1997 Jan 15;89(2):376-87 [9002938.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1438-46 [9083167.001]
  • [Cites] Cancer. 1997 Dec 1;80(11 Suppl):2199-204 [9395034.001]
  • [Cites] Genet Res. 1997 Oct;70(2):117-24 [9449188.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):606-11 [9554443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):166-75 [10508512.001]
  • [Cites] N Engl J Med. 2004 Dec 2;351(23):2403-7 [15575056.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):482-93 [15534356.001]
  • [Cites] Chem Biol Interact. 2005 May 30;153-154:187-95 [15935816.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12513-8 [16113082.001]
  • [Cites] J Exp Med. 2001 Feb 19;193(4):531-43 [11181704.001]
  • (PMID = 18552208.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA101937; United States / NCI NIH HHS / CA / P30 CA091842; United States / NIDDK NIH HHS / DK / T35 DK074375; United States / NCI NIH HHS / CA / P30 CA91842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  • [Other-IDs] NLM/ PMC2515115
  •  go-up   go-down


38. Bacher U, Haferlach T, Alpermann T, Zenger M, Kröger N, Beelen DW, Kern W, Schnittger S, Haferlach C: Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. Biol Blood Marrow Transplant; 2010 Dec;16(12):1649-57
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.
  • Relapse of acute myelogenous leukemia has been associated with clonal cytogenetic evolution, but no study focused specifically on relapse after allogeneic hematopoietic stem cell transplantation (HSCT).
  • We compared karyotypes in 160 patients at both diagnosis and relapse either after allo-HSCT (n = 26) or standard chemotherapy (n = 134) using chromosome banding analysis combined with fluorescein in situ hybridization.
  • At diagnosis, aberrant karyotypes were more frequent in the HSCT than in the chemotherapy cohort (16 of 26; 61.5% versus 63 of 134; 47.0%).
  • Differences in the karyotypes between diagnosis and relapse were more frequent in the allo-cohort (14 of 26; 53.8% versus 49 of 134; 36.6%) than in the conventional cohort (n.s.
  • The mean number of cytogenetic alterations per patient was increasing from 2.0 at diagnosis to 4.0 at relapse in the allo-cohort, in the conventionally treated patients from 0.9 to 1.3 (both P < .001).
  • Thus, higher frequencies of clonal evolution and increasing cytogenetic complexity were observed in the stem cell recipients probably related to the more unfavorable cytogenetic profiles already depicted at diagnosis.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20558312.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Guinan EC: Acquired aplastic anemia in childhood. Hematol Oncol Clin North Am; 2009 Apr;23(2):171-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In comparison to past decades, children who have acquired aplastic anemia (AA) enjoy excellent overall survival that reflects improvements in supportive care, more accurate exclusion of children who have alternate diagnoses, and advances in transplantation and immunosuppressive therapy (IST).
  • In this latter group, the barriers to overall and complication-free survival include recurrence of AA, clonal evolution with transformation to myelodysplasia/acute myelogenous leukemia, and therapy-related toxicities.
  • Improvements in predicting responses to IST, in alternative-donor HSCT, and in rationalizing therapy by understanding the pathophysiology in individual patients are likely to improve short- and long-term outcomes for these children.
  • [MeSH-major] Anemia, Aplastic / diagnosis. Anemia, Aplastic / therapy. Hematopoietic Stem Cell Transplantation

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327578.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83HN0GTJ6D / Cyclosporine; PVI5M0M1GW / Filgrastim
  • [Number-of-references] 160
  •  go-up   go-down


40. Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Geffroy S, Laï JL, Nicolini FE, Preudhomme C, Fi-LMC group: RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood; 2008 Apr 1;111(7):3735-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs).
  • Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression.
  • In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Blast Crisis / genetics. Core Binding Factor Alpha 2 Subunit / genetics. DNA-Binding Proteins / genetics. Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / genetics. Leukemia / genetics. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Transcription Factors / genetics. Trisomy / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Benzamides. Chromosomes, Human. Chronic Disease. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Myelodysplastic Syndromes / chemically induced. Myelodysplastic Syndromes / genetics. Myelodysplastic Syndromes / metabolism. Myelodysplastic Syndromes / mortality. Phenotype. Point Mutation. Retrospective Studies. Survival Rate. Translocation, Genetic / drug effects. Translocation, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202228.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / PRDM16 protein, human; 0 / Piperazines; 0 / Pyrimidines; 0 / RUNX1 protein, human; 0 / Transcription Factors; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [General-notes] NLM/ Investigator list not found.
  •  go-up   go-down


41. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P: Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci; 2009 Aug;41(1):33-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD34+ peripheral blood hematopoietic stem cells (HSC) are usually collected following mobilization therapy accomplished by using growth factors (GF) such as rHuG-CSF or rHuGM-CSF with or without chemotherapy.
  • In fact, 5-46% of patients who underwent mobilization therapy fail HSC collection due to very low peripheral blood HSC CD34+ count.
  • Patients' characteristics, including age, sex, stage of the underlying disease (complete or partial remission), diagnosis, previously administered radio/chemotherapy regimens, time-lapse from last chemotherapy before mobilization and mobilization schedule (including dose of GF) were considered as possibly predictive of poor or failed mobilization.
  • Therefore, a patient who fails a first mobilization (and when an HLA-compatible related on unrelated donor is not available) could undergo a second attempt either with different mobilization schedule or by using different GF, such as stem cell factor, growth hormone (GH), or more recently newly introduced drugs such as AMD3100, alone or in combination with rHuG- or -rHuGM-CSF.
  • [MeSH-minor] Adult. Antigens, CD34 / blood. Follow-Up Studies. Hematopoiesis. Hematopoietic Stem Cell Mobilization / methods. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myeloid, Acute / surgery. Lymphoma, Non-Hodgkin / surgery. Multiple Myeloma / surgery. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540167.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


42. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, Porter DL, Uberti JP, King RJ, Confer DL: Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant; 2008 Sep;14(9 Suppl):8-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic myelogenous leukemia (CML) was previously the most common diagnosis for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients.
  • Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML.
  • Treatment-related mortality (TRM) has declined significantly over the years, particularly in association with myeloablative transplant preparative regimens.
  • [MeSH-minor] Adult. Aged. Hematologic Neoplasms / therapy. History, 20th Century. History, 21st Century. Humans. Middle Aged. Registries. Survival Rate. Tissue Donors. Transplantation, Homologous. United States

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721775.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


43. Parikh SH, Mendizabal A, Martin PL, Prasad VK, Szabolcs P, Driscoll TA, Kurtzberg J: Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. Biol Blood Marrow Transplant; 2009 Aug;15(8):948-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age was 11.1 years (range: 1.1-19.7), median weight was 38.6 kg (range: 9.6-62.6), 61% of patients were male, and median time from diagnosis to transplant was 6.6 months (range: 2.0-61.4).
  • Patients with acute myelogenous leukemia (AML) were excluded.
  • Three patients developed acute GVHD (aGVHD) grades II-IV with a cumulative incidence at 100 days of 13% (95% CI 0.0%-27.1.0%).
  • UUCB should be actively considered for pediatric MDS patients lacking matched related or unrelated adult donors.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Adolescent. Adult. Anemia, Refractory, with Excess of Blasts. Chemoprevention / methods. Child. Female. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Tissue Donors. Treatment Outcome. Whole-Body Irradiation. Young Adult






Advertisement